Lisata Therapeutics, Inc. LSTA
Regular-session close
After hours · Nov 13, 4:00 PM ET
- YTD
- -34.95%
- 1 year
- -41.55%
- Market cap
- 13.07M
- EPS (ttm)
- -1.64
- Shares out
- 8.39M
- Forward P/E
- -1.20
- YTD return
- -34.95%
- 1-year return
- -41.55%
- Volume
- 104.86K
- Avg volume
- 304.42K
- Open
- 1.25
- Previous close
- 1.28
- Day's range
- 1.20 – 1.26
- 52-week range
- 0.96 – 5.07
- Beta
- 1.22
- Analysts
- Strong Buy
- Price target
- 14.00 (+1057.0%)
Key statistics
- Enterprise value
- -15.08M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -13.25M
- Total cash
- 38.26M
- Total debt
- 223.00K
- Return on equity
- -44.03%
- Short % of float
- 0.25%
- 50-day average
- 2.82
- 200-day average
- 3.03
Fundamental scorecard
6 of 25 checks passed on LSTA’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.75 | -0.59 | +0.16 | +21.33% |
| Aug 12, 2024 | Jun 1, 2024 | -0.75 | -0.61 | +0.14 | +18.67% |
| May 9, 2024 | Mar 1, 2024 | -0.73 | -0.65 | +0.08 | +10.96% |
| Feb 29, 2024 | Dec 1, 2023 | -0.86 | -0.66 | +0.20 | +23.26% |
| Nov 2, 2023 | Sep 1, 2023 | -0.93 | -0.65 | +0.28 | +30.11% |
| Aug 14, 2023 | Jun 1, 2023 | -0.70 | -0.50 | +0.20 | +28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lisata.com
News
12 Health Care Stocks Moving In Wednesday's Intraday Session Lisata’s Subsidiary Marea Therapeutics Reports Phase 2b TYDAL-TIMI 78 Data Showing Up To 72.2% Triglyceride Reduction With MAR001, Meeting All Part A Objectives
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine Lisata’s Marea Therapeutics Announces First Patient Dosed In Its Phase 2 Clinical Trial Of MAR002 For Treatment Of Acromegaly
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
12 Health Care Stocks Moving In Thursday's Intraday Session Lisata Acquires Marea Therapeutics And Secures $225M Financing To Advance Next-Generation Medicines For Cardioendocrine Diseases
12 Health Care Stocks Moving In Friday's Intraday Session Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees
12 Health Care Stocks Moving In Tuesday's After-Market Session
Your note
Sign in to keep a note on LSTA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AZAB MOHAMMAD | Director | Stock Award(Grant) | Jan 8, 2024 | 58,680 |
| BROWN GREGORY B | Director | Stock Award(Grant) | Jan 8, 2024 | 49,414 |
| BUCK KRISTEN K | Officer | Stock Award(Grant) | Sep 30, 2024 | 62,672 |
| FLOWERS CYNTHIA LOUISE | Director | Stock Award(Grant) | Jan 8, 2024 | 49,201 |
| HENSON HEIDI | Director | Stock Award(Grant) | Jan 8, 2024 | 39,480 |
| KLOSK STEVEN MARK | Director | Stock Award(Grant) | Jan 8, 2024 | 49,570 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BML Capital Management, LLC | 3.39% | 284,669 | 859.70K | Sep 29, 2024 |
| Vanguard Group Inc | 2.22% | 186,366 | 562.83K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.23% | 103,622 | 312.94K | Sep 29, 2024 |
| Blackrock Inc. | 0.67% | 56,013 | 169.16K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.66% | 55,681 | 168.16K | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 0.21% | 17,340 | 52.37K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.52% | 127,737 | 385.76K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.69% | 57,596 | 173.94K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.47% | 39,405 | 119.00K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 5,461 | 16.49K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Equity ETF | 0.05% | 3,851 | 11.63K | Jul 30, 2024 |
| Fidelity Total Market Index Fund | 0.05% | 4,379 | 13.22K | Oct 30, 2024 |
